SCHEMBL4597231

SCHEMBL4597231

Cc1cccc2c1C(=O)C(=O)N2c1cccs1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
DPP4 P27487 1/20 0.35
MGLL Q99685 1/20 0.34
AADAT Q8N5Z0 1/20 0.33
LMNA P02545 2/20 0.33
EGLN1 Q9GZT9 1/20 0.32
GAA P10253 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NR1H2 P55055 1/20 0.32
NR1H3 Q13133 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32
CASP1 P29466 1/20 0.32
HSD17B10 Q99714 1/20 0.32
ALOX5 P09917 1/20 0.32
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21474631 0.77 DPP4 (0.37) MEN1KMT2ADPP4NR1H2NR1H3
SCHEMBL5703450 0.74 ALDH1A1 (0.56) MEN1KMT2AMGLLGAAALDH1A1
SCHEMBL7756746 0.70 TTR (0.52) MEN1KMT2ADPP4MGLLAADAT
SCHEMBL5803629 0.68 AADAT (0.46) MEN1KMT2ADPP4MGLLAADAT
SCHEMBL14880102 0.65 MEN1 (0.46) MEN1KMT2ADPP4MGLLAADAT
SCHEMBL606359 0.64 KMT2A (0.49) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL31231930 0.64 KMT2A (0.49) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL20062962 0.63 TLR9 (0.34) MEN1KMT2AEGLN1GAASMN1; SMN2
SCHEMBL191887 0.63 TLR9 (0.44) MGLL
SCHEMBL13296023 0.63 MAOA (0.42) MEN1KMT2ALMNAEGLN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008046083-A2 USE OF OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-04-17 WO disclosed
EP-1877378-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2008-01-16 EP disclosed
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2007-05-10 US disclosed
WO-2006113864-A2 OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105820-A1 Oxindole compounds and their uses as therapeutic agents OPRL1, OPRK1, TRPV1 MEN1 4040/4885KMT2A 4075/4885DPP4 3008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.